(0.27%) 5 145.50 points
(0.29%) 38 554 points
(0.36%) 17 911 points
(-0.83%) $83.15
(1.35%) $1.949
(-0.17%) $2 343.30
(0.15%) $27.58
(0.88%) $930.20
(-0.29%) $0.932
(-0.40%) $10.98
(-0.39%) $0.797
(0.25%) $92.11
@ $4.83
发出时间: 14 Feb 2024 @ 22:35
回报率: -93.39%
Live Chart Being Loaded With Signals
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries...
Stats | |
---|---|
今日成交量 | 2.48M |
平均成交量 | 959 835 |
市值 | 34.47M |
EPS | $0 ( 2024-03-25 ) |
下一个收益日期 | ( $0 ) 2024-05-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.390 |
ATR14 | $0.00600 (1.80%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-02 | Gu Ehong | Sell | 1 731 | Ordinary Shares |
2024-04-09 | Gu Ehong | Sell | 17 889 | Ordinary Shares |
2024-02-15 | Poukalov Konstantin | Buy | 36 300 | Ordinary Shares |
2024-02-15 | Poukalov Konstantin | Sell | 19 218 | Ordinary Shares |
2024-02-15 | Poukalov Konstantin | Sell | 36 300 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
70.87 |
Last 79 transactions |
Buy: 50 859 501 | Sell: 7 434 951 |
音量 相关性
LianBio 相关性 - 货币/商品
LianBio 财务报表
Annual | 2022 |
营收: | $0 |
毛利润: | $-1.00M (0.00 %) |
EPS: | $-1.020 |
FY | 2022 |
营收: | $0 |
毛利润: | $-1.00M (0.00 %) |
EPS: | $-1.020 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-2.03 |
FY | 2020 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-1.450 |
Financial Reports:
No articles found.
LianBio
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor for ulcerative colitis and Crohn's disease; NX-13 for ulcerative colitis; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03, an eye solution for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。